What is the recommended protocol for intralesional immunotherapy with Candida albicans antigen to treat recalcitrant cutaneous warts?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Intralesional Candida Albicans Antigen Immunotherapy for Recalcitrant Warts

For recalcitrant cutaneous warts, inject 0.3-0.5 mL of purified Candida albicans antigen (CANDIN®) intralesionally into the largest wart every 2 weeks for up to 5 sessions, with the higher 0.5 mL volume providing superior clearance of both treated and distant untreated warts.

Recommended Protocol

Patient Selection

  • Use for warts resistant to standard destructive therapies (salicylic acid, cryotherapy) 1
  • Verify positive delayed-type hypersensitivity (DTH) to Candida antigen before treatment 2
  • Most effective for common warts, plantar warts, and plane warts 3

Dosing Regimen

Optimal dosing based on highest quality evidence:

  • 0.5 mL injected into a single largest wart provides the best outcomes 4
  • Alternative: 0.3 mL into single wart (still effective but less robust) 4
  • Repeat injections every 2 weeks until complete clearance or maximum 5 sessions 5, 6
  • Adjust to every 3 weeks if local tolerance issues develop 4

The 2025 phase IIa randomized trial demonstrated that 0.5 mL dosing achieved 79.5% complete clearance of injected warts versus 41.9% with placebo (RR 1.89, P=0.0007), and was the only regimen showing significant clearance of distant untreated warts (RR 3.2, P=0.001) 4. This represents the most rigorous evidence available and contradicts typical off-label practice using only 0.3 mL.

Administration Technique

  • Inject intralesionally (intradermally into the wart itself), not subcutaneously 7
  • Target the largest or "mother" wart only 5, 2
  • Use local anesthesia if needed for patient comfort 1
  • Critical safety point: Avoid digital vasculature when treating periungual/subungual warts to prevent fingertip ischemia 8

Expected Outcomes

Efficacy rates from high-quality studies:

  • Complete clearance of treated warts: 72-94% depending on concentration 3, 5
  • Clearance of distant untreated warts: 56-77% (systemic immune response) 4, 2
  • Superior to intralesional zinc sulfate (74% clearance) and PPD (56% clearance) 3, 5
  • Comparable or superior to topical podophyllin for genital warts 9

The 2023 study showed Candida antigen 1/100 concentration achieved 94.3% complete clearance versus 77.1% with 1/1000 concentration, suggesting higher concentrations are more effective 3.

Clinical Considerations

Advantages Over Other Treatments

  • Single wart injection clears distant warts through systemic cell-mediated immunity 1, 2
  • Less painful than intralesional zinc sulfate 3
  • Lower recurrence rates compared to destructive therapies 6
  • Cost-effective with minimal treatment sessions required 5

Adverse Effects

  • Most common: Pain during injection (manageable with local anesthesia) 2
  • Local erythema and induration at injection site (expected DTH response) 7
  • Rare but serious: Digital ischemia/soft tissue necrosis if injected near digital vessels 8
  • Systemic reactions are extremely rare but epinephrine 1:1000 should be immediately available 7

Contraindications and Precautions

  • Avoid in pregnancy unless clearly needed 7
  • Use caution in immunosuppressed patients (may have diminished response) 7
  • Patients on corticosteroids may have suppressed DTH response 7
  • Those on beta-blockers may be refractory to epinephrine if anaphylaxis occurs 7

When to Consider Alternative or Combination Therapy

  • If no response after 3-5 sessions, consider triple-antigen immunotherapy (Candida + PPD + MMR), which achieved 77.5% clearance in resistant cases 6
  • For plantar warts with thick keratin, combine with aggressive paring before injection 1
  • British Association of Dermatologists guidelines classify intralesional immunotherapy as level of evidence 1, though note clearance rates range from 47-87% across studies 1

Follow-Up

  • Assess response at each 2-week visit before next injection
  • Monitor for 6 months post-treatment to document sustained clearance and detect recurrences 2
  • No relapses were observed in responders during 6-month follow-up in multiple studies 4, 2

The evidence strongly supports using the higher 0.5 mL volume of purified Candida antigen rather than the traditional 0.3 mL dose, as this provides significantly better clearance of both treated and distant warts with acceptable tolerability 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.